阿莫西林-克拉维酸钾、左氧氟沙星治疗下呼吸道感染的疗效及成本-效果分析  

Efficacy and Cost-effectiveness Analysis of Amoxicillin-clavulanate Potassium and Levofloxacin in Treatment of Lower Respiratory Tract Infection

作　　者：曾小兰 ZENG Xiao-lan(Department of Infection,Yongfeng County People's Hospital,Yongfeng 331500,Jiangxi,China)

机构地区：[1]永丰县人民医院感染科,江西永丰331500

出　　处：《医学信息》2022年第18期77-79,共3页Journal of Medical Information

摘　　要：目的研究阿莫西林-克拉维酸钾、左氧氟沙星治疗下呼吸道感染的疗效及成本-效果。方法选择2016年2月-2018年2月在我院诊治的60例下呼吸道感染患者为研究对象,依照随机数字表法将研究对象分为对照组和观察组,各30例。对照组患者给予左氧氟沙星治疗,观察组采用阿莫西林-克拉维酸钾治疗,比较两组临床治疗总有效率、成本-效果、炎性因子水平以及临床不良反应发生情况。结果观察组治疗率总有效率为93.33%,高于对照组的73.33%(P<0.05);两组成本-效果比较,差异无统计学意义(P>0.05);两组治疗后WBC、N、CRP均低于治疗前,且观察组低于对照组(P<0.05);观察组不良反应发生率为33.33%,与对照组的36.67%比较,差异无统计学意义(P>0.05)。结论阿莫西林-克拉维酸钾治疗下呼吸道感染效果优于左氧氟沙星,可提高治疗总有效率,降低炎性因子水平,且未增加不良反应,有助于提升成本-效果。Objective To study the efficacy and cost-effectiveness of amoxicillin clavulanate potassium and levofloxacin in the treatment of lower respiratory tract infection.Methods Sixty patients with lower respiratory tract infection diagnosed and treated in our hospital from February 2016 to February 2018 were selected as the research objects.They were divided into control group and observation group by random number table method,with 30 cases in each group.The control group was treated with levofloxacin,and the observation group was treated with amoxicillin-clavulanate potassium.The total effective rate,cost-effectiveness,inflammatory factor level and incidence of clinical adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 93.33%,which was higher than 73.33%of the control group(P<0.05).There was no significant difference in cost-effectiveness between the two groups(P>0.05).The WBC,N and CRP of the two groups after treatment were lower than those before treatment,and the observation group was lower than the control group,the(P<0.05).The incidence of adverse reactions in the observation group was 33.33%,which was compared with 36.67%in the control group(P>0.05).Conclusion Amoxicillin-clavulanate potassium is better than levofloxacin in the treatment of lower respiratory tract infection,which can improve the total effective rate,reduce the level of inflammatory factors,and will not increase the adverse reactions,improve the cost-effectiveness,and has significant application advantages.

关 键 词：阿莫西林克拉维酸钾 左氧氟沙星 下呼吸道感染 成本-效果 

分 类 号：R56[医药卫生—呼吸系统]